MIP-3 alpha (CCL20) Human ProcartaPlex™ Simplex Kit - Citations

MIP-3 alpha (CCL20) Human ProcartaPlex™ Simplex Kit - Citations

View additional product information for MIP-3 alpha (CCL20) Human ProcartaPlex™ Simplex Kit - Citations (EPX01A-12128-901)

Showing 1 product Citations

Citations & References
Abstract
In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment.
AuthorsChitadze G, Flüh C, Quabius ES, Freitag-Wolf S, Peters C, Lettau M, Bhat J, Wesch D, Oberg HH, Luecke S, Janssen O, Synowitz M, Held-Feindt J, Kabelitz D
JournalOncoimmunology
PubMed ID29147621
Despite aggressive treatment regimens based on surgery and radiochemotherapy, the prognosis of patients with grade IV glioblastoma multiforme (GBM) remains extremely poor, calling for alternative options such as immunotherapy. Immunological mechanisms including the Natural Killer Group 2 member D (NKG2D) receptor-ligand system play an important role in tumor immune surveillance ... More